Phase I Trial of Everolimus and Capecitabine in Metastatic HER2− Breast Cancer

The all-oral regimen of everolimus with capecitabine is active and well tolerated, with encouraging results for progression-free survival, overall survival, and clinical benefit rate in patients with MBC.